中国药物经济学2024，Vol.19Issue(11)：45-52,57,9.DOI:10.12010/j.issn.1673-5846.2024.11.009
替尔泊肽治疗成人2型糖尿病疗效和安全性的Meta分析
Efficacy and Safety of Tirzepatide in the Treatment of Type 2 Diabetes Mellitus in Adults:A Meta-analysis
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of tirzepatide compared with other types of antidiabetic drugs in adults with type 2 diabetes mellitus(T2DM).Methods PubMed,Embase,Cochrane Library,Web of Science,ClinicalTrials.gov,CNKI,Wanfang Database,VIP database and China Biology Medicine Disc were searched by computer.The randomized controlled trials(RCT)of tirzepatide 5 mg,10 mg,15 mg versus placebo or other antidiabetic drugs in the treatment of T2DM were collected.The search time limit was from the establishment of the database to September 2023.After literature screening,data extraction and quality evaluation,RevMan 5.4 software was used for Meta-analysis.Results A total of 10 RCT studies were included,with a total of 9 526 patients.The results of meta-analysis showed that compared with placebo,basal insulin and glucagon-like peptide-1 receptor agonist(GLP-1RA),tirzepatide was more effective in reducing patients'HbA1c,significantly improving the HbA1c compliance rate,and significantly reducing body weight,with statistical significance(P＜0.05).The effect was dose-dependent.In terms of safety,tirzepatide had a higher incidence of adverse events(AE),mainly gastrointestinal adverse events,but the incidence of hypoglycemia was lower than that of placebo[RR=0.65,95%CI(0.47,0.90),P＜0.05]and basal insulin[RR=0.56,95%CI(0.43,0.72),P＜0.05].Dose subgroup analysis showed that the occurrence of adverse reactions increased with the increase of dose.Conclusion Compared with placebo,basal insulin and GLP-1RA,tirzepatide has good hypoglycemic and weight loss effects in a dose-dependent manner,and does not significantly increase the risk of gastrointestinal reactions and hypoglycemia.关键词
胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽双受体激动剂/替尔泊肽/2型糖尿病/有效性/安全性/Meta分析Key words
Dual GLP-1/GIP receptor agonist/Tirzepatide/Type 2 diabetes mellitus/Efficacy/Safety/Meta-analysis分类
医药卫生引用本文复制引用
高宁,冯冰,高胜男,刘洋,牛梦娜,郭珊,刘国强..替尔泊肽治疗成人2型糖尿病疗效和安全性的Meta分析[J].中国药物经济学,2024,19(11):45-52,57,9.基金项目
河北省自然科学基金项目(NH2021206407) （NH2021206407）
